Douglas K. Marks
YOU?
Author Swipe
View article: Whole transcriptome analysis reveal MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancer
Whole transcriptome analysis reveal MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancer Open
Introduction: Early lymph node (LN) metastasis often precedes systemic metastasis and corresponds with significantly inferior survival for patients diagnosed with early-stage breast cancer (EBC). To understand the biological pathways invol…
View article: Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer Open
Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response…
View article: Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer Open
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for descr…
View article: Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer Open
The clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen recep…
View article: Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Supplemental Figure 1: Flow chart for database Supplemental Figure 2: Representation of Tissue segmentation Supplemental Figure 3: Representation of Cell Segmentation Supplemental Figure 4: Representation of Phenotyping Supplemental Figure…
View article: SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Supplementary Pearson Correlation Matrix
View article: Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Supplementary ROC Curve and Univariable Cox results
View article: Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Novel methods to analyze the tumor microenvironment (TME) are urgently needed to stratify melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) analysis, by conventional pathologic methods, is predictive but is …
View article: Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Demographics for Unanalyzable Cohort
View article: Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Novel methods to analyze the tumor microenvironment (TME) are urgently needed to stratify melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) analysis, by conventional pathologic methods, is predictive but is …
View article: Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Demographics for DSS Cohort.
View article: Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Demographics for DSS Cohort.
View article: Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Supplemental Figure 1: Flow chart for database Supplemental Figure 2: Representation of Tissue segmentation Supplemental Figure 3: Representation of Cell Segmentation Supplemental Figure 4: Representation of Phenotyping Supplemental Figure…
View article: Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Supplementary ROC Curve and Univariable Cox results
View article: Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Demographics for Unanalyzable Cohort
View article: SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma Open
Supplementary Pearson Correlation Matrix
View article: Table S1 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Table S1 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
Comparison of patient demographics in validation cohort to original publication discovery and test cohorts.
View article: Supplemental Figure S3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Supplemental Figure S3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
DSP identifies differences in immune marker expression between patients with high and low HLA-DR- macrophage density. DSP analysis of immune markers per total CD45 including CD3, CD4, CD8A, CD68, CD163 as well as immunosuppressive or check…
View article: Table S2 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Table S2 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
Patient characteristics in metastasis cohort.
View article: Figure S1 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Figure S1 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
Melanoma Immune Profile (MIP) correlates with metastasis cohort including patients with local recurrence only.
View article: Supplemental Figure Legends from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Supplemental Figure Legends from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
Supplemental Figure Legends
View article: Data from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Data from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
Patients with resected stage II-III melanoma have approximately a 35% chance of death from their disease. A deeper understanding of the tumor immune microenvironment (TIME) is required to stratify patients and identify factors leading to t…
View article: Figure S3 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Figure S3 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
MIP correlates with OS.
View article: Figure S2 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Figure S2 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
Heat map showing relative levels of mRNA expression for each gene, specifying the gene represented by each row.
View article: Table S1 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Table S1 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
Comparison of patient demographics in validation cohort to original publication discovery and test cohorts.
View article: Supplementary Figure S1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Supplementary Figure S1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
CD8/CD68 ratio is predictive of recurrence. Receiver Operating Characteristic (ROC) curve analysis for visceral recurrence (n=52, AUC=0.684, p=0.0350 by Mann-Whitney U test).
View article: Supplemental Table ST2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Supplemental Table ST2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
Patient characteristics of the metastatic melanoma cohort.
View article: Supplemental Table ST2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Supplemental Table ST2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
Patient characteristics of the metastatic melanoma cohort.
View article: Supplemental Table ST3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
Supplemental Table ST3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma Open
Patient characteristics of the DSP cohort.
View article: Supplementary Figure Legends from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Supplementary Figure Legends from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma Open
Figure legends for supplementary figures.